Linnet Biopharmaceuticals

Linnet Biopharmaceuticals is a clinical-stage biotechnology company dedicated to developing innovative therapies for Central Nervous System (CNS) disorders, with a primary focus on Attention Deficit Hyperactivity Disorder (ADHD) and related neurodevelopmental conditions. The company's lead program, LN-001, is a proprietary fixed-dose combination of a stimulant and a glutamate modulator designed to improve efficacy and reduce side effects compared to current standard-of-care treatments. Linnet leverages a strategy of combining well-characterized agents to address unmet needs in pediatric and adult populations, specifically targeting the "rebound" effect often seen with stimulants. The company is currently advancing its pipeline through mid-stage clinical trials to validate its multi-modal approach to neuropsychiatric care. Linnet is headquartered in Skillman, New Jersey, and is led by a team with extensive experience in CNS drug development and commercialization.